Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.
Bosly A, Grigg A, Holte H, Gisselbrecht C, Radford J, Rossi A, Lopez-Guillermo A, Trneny M, Sebban C, Hagberg H, Leal da Costa F, Colombat P, Bron D, Coiffier B. Bosly A, et al. Among authors: colombat p. Oncologist. 2013;18(11):1189. doi: 10.1634/theoncologist.2013-0223. Epub 2013 Oct 8. Oncologist. 2013. PMID: 24105750 Free PMC article. Clinical Trial.
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, Moretti L, Colombat P, Luminari S, Fabbiano F, Di Renzo N, Goldstone A, Carella AM; EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. Federico M, et al. Among authors: colombat p. J Clin Oncol. 2003 Jun 15;21(12):2320-5. doi: 10.1200/JCO.2003.11.103. J Clin Oncol. 2003. PMID: 12805333 Clinical Trial.
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results.
Carella AM, Bellei M, Brice P, Gisselbrecht C, Visani G, Colombat P, Fabbiano F, Donelli A, Luminari S, Feugier P, Browett P, Hagberg H, Federico M. Carella AM, et al. Among authors: colombat p. Haematologica. 2009 Jan;94(1):146-8. doi: 10.3324/haematol.13484. Epub 2008 Nov 10. Haematologica. 2009. PMID: 19001284 Free PMC article. No abstract available.
Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
André M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht C. André M, et al. Among authors: colombat p. J Clin Oncol. 1999 Jan;17(1):222-9. doi: 10.1200/JCO.1999.17.1.222. J Clin Oncol. 1999. PMID: 10458237
Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.
Gorin NC, Coiffier B, Hayat M, Fouillard L, Kuentz M, Flesch M, Colombat P, Boivin P, Slavin S, Philip T. Gorin NC, et al. Among authors: colombat p. Blood. 1992 Sep 1;80(5):1149-57. Blood. 1992. PMID: 1515637 Free article. Clinical Trial.
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haïoun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boué F, Taillan B, Lederlin P, Najman A, Thièblemont C, Montestruc F, Mathieu-Boué A, Benzohra A, Solal-Céligny P. Colombat P, et al. Blood. 2001 Jan 1;97(1):101-6. doi: 10.1182/blood.v97.1.101. Blood. 2001. PMID: 11133748 Free article. Clinical Trial.
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. Colombat P, et al. Bone Marrow Transplant. 2006 Sep;38(6):417-20. doi: 10.1038/sj.bmt.1705452. Bone Marrow Transplant. 2006. PMID: 16951691 Clinical Trial.
199 results